BI 1569912 vs Esketamine (CLE-100)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Reported efficacy
Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)
Result source: NCT06558344
Esketamine (CLE-100)
Developed by Clexio Biosciences
NCT04103892 · Phase 2 · completed
The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.
Reported efficacy
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)
Result source: NCT06340958
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BI 1569912 | Esketamine (CLE-100) |
|---|---|---|
| MADRS, change (acute) | -12.3 vs -12−0.3 vs placeboNCT0628023510 other results
| -10.7 vs -9.5−1.3 vs placeboNCT041038922 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | 34.8% vs 33.8%+1 vs placeboNCT062802355 other results
| —Not reported |
| MADRS remission | 21.2% vs 19.7%+1.5 vs placeboNCT062802352 other results
| —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- BI 1569912
- -12.3 vs -12−0.3 vs placeboNCT06280235
10 other results
- -10 vs -10.3 NCT06558344
- -19.9 vs -19.3 NCT04937829
- -11.9 vs -12 NCT06280235
- -10.6 vs -10.3 NCT06558344
- -7.8 vs -12 NCT06280235
- -13.6 vs -10.3 NCT06558344
- -16.8 vs -19.3 NCT04937829
- -5.7 vs -6.4 NCT06280235
- -5.9 vs -6.4 NCT06280235
- -5.2 vs -6.4 NCT06280235
- Esketamine (CLE-100)
- -10.7 vs -9.5−1.3 vs placeboNCT04103892
2 other results
- -11.7 vs -8.7 NCT06340958
- -13.0 vs -7.7 NCT04103892
CGI-S, change (acute)
- BI 1569912
- —Not reported
- Esketamine (CLE-100)
- —Not reported
MADRS response
- BI 1569912
- 34.8% vs 33.8%+1 vs placeboNCT06280235
5 other results
- 15.5% vs 11.3% NCT06280235
- 31.4% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- 20.6% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- Esketamine (CLE-100)
- —Not reported
MADRS remission
- BI 1569912
- 21.2% vs 19.7%+1.5 vs placeboNCT06280235
2 other results
- 25.7% vs 19.7% NCT06280235
- 8.8% vs 19.7% NCT06280235
- Esketamine (CLE-100)
- —Not reported
Relapse (% of patients)
- BI 1569912
- —Not reported
- Esketamine (CLE-100)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BI 1569912: 4 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BI 1569912 | Esketamine (CLE-100) |
|---|---|---|
| Dropout rate | 9.6%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results7.3%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 12.5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 9.6%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 14.6%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 17.1%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%20 mg NCT04937829 · Phase 1 15%5 mg NCT04937829 · Phase 1 | 7.7%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results8.3%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | 2.4%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results4.9%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2.7%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 4.9%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —20 mg NCT04937829 · Phase 1 —5 mg NCT04937829 · Phase 1 | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 8% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 1.2%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results2.4%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 2.4%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT04937829 · Phase 1 0%5 mg NCT04937829 · Phase 1 | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 20 mga dizziness 8.4% (placebo 2.5%) headache 8.4% (placebo 6.3%) nasopharyngitis 4.8% (placebo 3.8%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results10 mg headache 4.9% (placebo 6.3%) upper respiratory tract infection 2.4% (placebo 6.3%) dizziness 0% (placebo 2.5%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 7.5% (placebo 6.3%) nasopharyngitis 7.5% (placebo 3.8%) upper respiratory tract infection 5% (placebo 6.3%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg headache 12.3% (placebo 7.9%) nasopharyngitis 8.2% (placebo 3.9%) diarrhoea 2.7% (placebo 1.3%) NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 10 mg headache 9.8% (placebo 7.9%) diarrhoea 4.9% (placebo 1.3%) nasopharyngitis 4.9% (placebo 3.9%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 14.3% (placebo 7.9%) diarrhoea 5.7% (placebo 1.3%) upper respiratory tract infection 5.7% (placebo 1.3%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg decreased appetite 5% (placebo 5.3%) blood pressure increased 0% (placebo 0%) constipation 0% (placebo 0%) NCT04937829 · Phase 1 5 mg blood pressure increased 10% (placebo 0%) constipation 10% (placebo 0%) headache 5% (placebo 5.3%) NCT04937829 · Phase 1 | dizziness 30.8% (placebo 0%) somnolence 15.4% (placebo 0%) alanine aminotransferase increased 7.7% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more resultsdizziness 13.9% (placebo 0%) headache 12.5% (placebo 0%) somnolence 11.1% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 dizziness 18% (placebo 4.1%) nausea 18% (placebo 0%) headache 12% (placebo 2%) NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BI 1569912
show 5 more results
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Esketamine (CLE-100)'s landscape